The evolution of drug resistance in Mycobacterium tuberculosis: From a mono-rifampin-resistant cluster into increasingly multidrug-resistant variants in an HIV-seropositive population

Journal of Infectious Diseases

Volumn 198, Issue 1, 2008, Pages 90-94

  Bifani, Pablo ^a   Mathema, Barun ^b,c   Kurepina, Natalia ^b   Shashkina, Elena ^b   Bertout, Julie ^f   Blanchis, Anne Sophie ^f   Moghazeh, Soraya ^b   Driscoll, Jeffrey ^d   Gicquel, Brigitte ^g   Frothingham, Richard ^e   Kreiswirth, Barry N ^b  

^a PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c Columbia University ^*  (United States)

^d WADSWORTH CENTER   (United States)

^e DURHAM VA MEDICAL CENTER   (United States)

^f INSERM   (France)

^g INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG SENSITIVITY; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SEQUENCE ANALYSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EVOLUTION; HIV INFECTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 46349091974     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/588822     Document Type: Article

References (15)

1. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283:2537-45.
2. Lutfey M, Della-Latta P, Kapur V, et al. Independent origin of monorifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med 1996; 153:837-40.
3. Munsiff SS, Joseph S, Ebrahimzadeh A, Frieden TR. Rifampin-monoresistant tuberculosis in New York City, 1993-1994. Clin Infect Dis 1997; 25:1465-7.
4. Peloquin CA. Tuberculosis drug serum levels. Clin Infect Dis 2001; 33:584-5.
5. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312:1944-6.
6. Munsiff SS, Bassoff T, Nivin B, et al. Molecular epidemiology of multidrug-resistant tuberculosis, New York City, 1995-1997. Emerg Infect Dis 2002; 8:1230-8.
7. van Embden JD, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993; 31:406-9.
8. Mathema B, Kurepina NE, Bifani PJ, Kreiswirth BN. Molecular epidemiology of tuberculosis: current insights. Clin Microbiol Rev 2006; 19:658-85.
9. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79:3-29.
10. Rad ME, Bifani P, Martin C, et al. Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family. Emerg Infect Dis 2003; 9:838-45.
11. Luria SE, Delbruck M. Mutations in bacteria from virus sensitivity to virus resistance. Genetics 1943; 28:491-511.
12. Morlock GP, Plikaytis BB, Crawford JT. Characterization of spontaneous, in vitro-selected, rifampin-resistant mutants of Mycobacterium tuberculosis strain H37Rv. Antimicrob Agents Chemother 2000; 44:3298-301.
13. MMWR. American Thoracic Society, CDC, and Infectious Disease Society of America, Recommendations and Reports. Treatment of Tuberculosis. MMWR Morb Mortal Wkly Rep 2003; 52:1-77.
14. Billington OJ, McHugh TD, Gillespie SH. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999; 43:1866-9.
15. Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 2003; 3:13-21.